Skip to content
Parakho

Akums Drugs and Pharmaceuticals Ltd

NSE AKUMSBSE 544222

Q1 FY27, unaudited

Revenue
₹1,166.63 Cr
Profit after tax
₹100.98 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations1,166.63+13.93%4,359.02
Other income30.38+13.65%128.73
Total income1,197.01+13.92%4,487.74
Employee benefit expense201.43+14.36%753.82
Finance costs24.76+7.01%94.07
Depreciation & amortisation41.07+11.23%154.55
Total expenses1,057.77+10.75%4,085.62
Profit before tax139.24+45.58%382.10
Tax expense38.26+23.57%125.70
Profit after tax100.98+56.11%256.40
Total comprehensive income104.09+56.70%257.32
Earnings per share
Earnings per share, basic₹6.53₹16.67
Earnings per share, diluted₹6.53₹16.67

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — unaudited, from the company’s filing with NSE. Source

Earnings call

Q4 FY26

Akums reported FY26 revenue of Rs 4,359 crore, up 5.8%, with adjusted EBITDA of Rs 522 crore, up 13.3%, and adjusted EBITDA margin at 12% versus 11.2% in FY25. CDMO delivered double-digit volume growth driven by existing customers, while the API and international branded formulation businesses remained weak through the year with trade generics turning EBITDA positive in Q4. Management discussed progress on European GMP accreditation, the Zambia partnership, an EU contract, and capacity expansion across injectables, Penem and Baddi facilities.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 56 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 25 Aug 2026.

Akums Drugs and Pharmaceuticals Ltd (AKUMS) — filings and results · Parakho